Ascletis Announces First Patient Dosed in the Phase III Clinical Trial of FASN Inhibitor ASC40 Combined with Bevacizumab for Treatment of Recurrent Glioblastoma

/PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) today announces the dosing of the first patient in the Phase III registration clinical trial of ASC40...

Related Keywords

China ,Shaoxing ,Zhejiang ,Hong Kong ,Hangzhou ,Chinese ,Wenbin Li ,Jinzij Wu ,Hong Kong Stock Exchange ,Tumor Treatment Center ,Capital Medical University ,Glioma Committee Of Chinese Cancer Association ,Ascletis Pharma Inc ,Prnewswire Ascletis Pharma Inc ,Vice Chairman ,Secretary General ,Glioma Committee ,Chinese Cancer Association ,Comprehensive Tumor Treatment Center ,Beijing Tiantan Hospital ,Capital Medical ,New Drug ,Hepatitisb Virus ,Primary Biliary Cholangitis ,